[144] Harmony Biosciences Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. (HRMY) filed a Form 144 reporting a proposed sale of 21,573 common shares, representing restricted stock units acquired on 03/29/2023. The sale is to be executed through Morgan Stanley Smith Barney LLC with an approximate aggregate market value of $787,630.23 and an indicated approximate sale date of 08/15/2025. The filing shows 57,532,601 shares outstanding and indicates no securities sold by the filer in the past three months. The filer certifies they are not aware of undisclosed material adverse information and discloses the sale is related to previously granted RSUs.

Positive

• Full disclosure of sale details including broker, quantity, acquisition nature, and planned sale date
• Securities acquired as RSUs — sale appears linked to compensation rather than external transfers
• No sales in prior three months, indicating this is not part of a rapid disposal pattern

Negative

• Insider sale reported, which some investors may view unfavorably despite small size

Insights

Securities Analyst

TL;DR: Small insider sale of previously granted RSUs via a broker; does not appear materially dilutive given outstanding share count.

The filing documents a planned sale of 21,573 shares acquired as restricted stock units on 03/29/2023. At an aggregate market value of $787,630.23 against 57,532,601 shares outstanding, the position is immaterial relative to the share base. The use of Morgan Stanley Smith Barney LLC as broker and the absence of other sales in the prior three months suggest routine settlement of compensation-related equity rather than a pattern of disposal. For investors, this is a disclosure of insider liquidity but lacks indicators of material corporate change.

Corporate Governance Expert

TL;DR: The filing shows standard compliance with Rule 144 for liquidation of RSUs; procedural transparency is appropriate.

The notice states the securities were acquired as RSUs from the issuer and specifies the broker, quantity, acquisition date, and planned sale date, meeting Rule 144 disclosure norms. The filer affirms no undisclosed material adverse information, and there are no recorded sales in the prior three months. From a governance perspective, this is routine disclosure of insider transactions tied to compensation and does not raise immediate red flags about governance or disclosure practices.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	21573	787630.23	57532601	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/29/2023	Restricted Stock Units	Issuer			21573	03/29/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Harmony Biosciences (HRMY) Form 144 report?

The Form 144 reports a proposed sale of 21,573 common shares acquired as restricted stock units on 03/29/2023, with an approximate aggregate market value of $787,630.23.

Who is the broker handling the HRMY sale?

The sale is to be executed through Morgan Stanley Smith Barney LLC located at 1 New York Plaza, New York, NY.

When is the planned sale date for the shares reported in the Form 144?

The filing indicates an approximate sale date of 08/15/2025.

How large is the sale relative to Harmony's outstanding shares?

The filing lists 57,532,601 shares outstanding; 21,573 shares represent an immaterial fraction of the total outstanding shares.

Has the filer sold other Harmony shares in the past three months?

The filing states Nothing to Report for securities sold during the past three months.